02-40000-24

Original Effective Date: 09/15/14

Reviewed: 08/27/26

Revised: 09/15/26

Subject: Fecal Microbiota Transplantation

THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION OF BENEFITS, OR A GUARANTEE OF PAYMENT, NOR DOES IT SUBSTITUTE FOR OR CONSTITUTE MEDICAL ADVICE. ALL MEDICAL DECISIONS ARE SOLELY THE RESPONSIBILITY OF THE PATIENT AND PHYSICIAN. BENEFITS ARE DETERMINED BY THE GROUP CONTRACT, MEMBER BENEFIT BOOKLET, AND/OR INDIVIDUAL SUBSCRIBER CERTIFICATE IN EFFECT AT THE TIME SERVICES WERE RENDERED. THIS MEDICAL COVERAGE GUIDELINE APPLIES TO ALL LINES OF BUSINESS UNLESS OTHERWISE NOTED IN THE PROGRAM EXCEPTIONS SECTION.

Position Statement	Billing/Coding	Reimbursement	Program Exceptions	Definitions	Related Guidelines
Other	References	Updates			

DESCRIPTION:

Fecal microbiota transplantation (FMT), also called donor feces infusion, intestinal microbiota transplantation, and fecal bacteriotherapy involves the duodenal infusion of intestinal microorganisms via the transfer of stool from a healthy individual into a diseased individual to restore normal intestinal flora. The stool can be infused as a liquid suspension into the upper gastrointestinal tract through a nasogastric tube or gastroscopy, into the colon through a colonoscope or rectal catheter, or administered orally via capsules (ie, encapsulated FMT).

The goal of FMT is to replace damaged and/or disordered native microbiota with a stable community of donor microorganisms. The treatment is based on the premise that an imbalance in the community of microorganisms residing in the gastrointestinal tract (ie, dysbiosis) is associated with specific disease states, including susceptibility to infection.

The human microbiota, defined as the aggregate of microorganisms (bacteria, fungi, archaea) on and in the human body, is believed to consist of approximately 10 to 100 trillion cells, approximately 10 times the number of human cells. Most human microbes reside in the intestinal tract, and most of these are bacteria. In its healthy state, intestinal microbiota perform a variety of useful functions including aiding in the digestion of carbohydrates, mediating the synthesis of certain vitamins, repressing growth of pathogenic microbes, and stimulating the lymphoid tissue to produce antibodies to pathogens.

Summary and Analysis of Evidence: Rokkas et al (2019) performed a systematic review and meta-analysis to assess the efficacy of fecal microbiota transplantation (FMT) for the treatment of recurrent Clostridium difficile (CDI). Six RCTs were included in the analysis (N=348), and 7 interventions were compared: dFMT, aFMT, vancomycin, vancomycin plus dFMT, vancomycin plus bowel lavage, fidaxomicin, and placebo). The primary outcome was the resolution of CDI-related symptoms. The network meta-analysis demonstrated that dFMT was superior to vancomycin, vancomycin plus dFMT, vancomycin plus bowel lavage, and fidaxomicin groups.

Tariq et al (2019) performed a systematic review and meta-analysis to assess the efficacy of FMT as a treatment option for recurrent CDI on the basis of results from open-label studies and placebo-controlled clinical trials. The authors were motivated to perform this analysis based on observations that FMT cure rates for CDI are high in observational studies (eg, >90%) but appear to be consistently lower in open-label studies and clinical trials. Thirteen studies were included for evaluation, including 6 placebo-controlled RCTs and 7 open-label studies. Out of 610 patients receiving FMT, 439 patients achieved

clinical cure; study heterogeneity was significant (I2 =91.35%). Cure rates were found to be lower in randomized trials versus open-label studies. Subgroup meta-analysis by FMT route of administration indicated lower cure rates with enema than colonoscopy. However, no differences between colonoscopy and oral delivery routes were detected. Lower cure rates were observed for studies that included both recurrent and refractory CDI than those that only included patients with recurrent CDI.

To investigate the long-term clinical outcomes of FMT in patients with CDI, Mamo et al (2018) conducted a retrospective study using a follow-up survey of 137 patients who had received FMT for recurrent CDI at a single-center between January 2012 and December 2016. Median time from last FMT to follow-up was 22 months. Overall at follow-up, 82% (113/137) of patients had no recurrence of CDI (nonrecurrent CDI group) and 18% (24/137) of patients had CDI (recurrent CDI group). The survey results suggested that antibiotic exposure for non-CDI infections after FMT were more common in the recurrent CDI group (75%) than in the nonrecurrent CDI group (38%). Overall, 82% of patients reported being symptom-free.

Tun et al (2022) performed a systematic review and meta-analysis to assess the efficacy of FMT for the treatment of CDI in children. The analysis included 904 children across 14 observational studies (5 prospective, 5 retrospective, and 4 case series); 12 studies included children with recurrent CDI and 2 studies included children with recurrent CDI or first episode of CDI. The most common route of FMT administration was colonoscopy (49.79%). The primary outcome was the efficacy of FMT in treating CDI or recurrent CDI. Results demonstrated a rate of success ranging between 66% and 100%, the latter of which was found in 7 studies. The pooled rate of clinical success in the overall cohort was 86%. There were 47 adverse events in 45 patients and 38 serious adverse events in 36 patients; the causes of serious adverse events were variable and there was no single predominant cause.

A systematic review and meta-analysis by Du et al (2021) evaluated the efficacy of FMT delivery via oral capsules for the treatment of recurrent CDI. The analysis included 12 case series and 3 RCTs (N=763 patients). Encapsulated delivery of FMT demonstrated an overall efficacy rate of 82.1%. There was no statistically significant difference in the efficacy of FMT capsules that used lyophilized stool versus frozen stool. There was also no statistically significant difference in the efficacy of FMT capsules compared with colonoscopy. No serious adverse events attributable to oral FMT capsules were reported, other than those associated with treatment failure.

Gangwani et al (2023) published a systematic review comparing fresh vs frozen vs lyophilized FMT for recurrent CDI. A total of 616 patients were included across 8 studies (4 RCT and 4 cohort); all 8 studies evaluated fresh FMT, 6 also assessed frozen FMT, and 3 assessed lyophilized FMT. Fresh FMT was determined to be most successful for the resolution of symptoms with 93% efficacy, followed by frozen at 88% efficacy and lyophilized at 83% efficacy. There were no significant differences in efficacy between frozen vs fresh FMT groups or frozen vs lyophilized groups.

A double-blind RCT by Lee et al (2016) compared fresh with frozen stool used in FMT to treat patients with recurrent CDI. A total of 232 patients were included, with 114 assigned to frozen FMT and 118 to fresh FMT. The primary endpoint was the proportion of patients with no recurrence of CDI-related diarrhea 13 weeks after FMT. The trial was designed as a noninferiority trial, with a margin of 15%. In the per-protocol population (n=178), clinical resolution of symptoms was reported in 76 (83.5%) of 91 patients in the frozen FMT group and 74 (85.1%) of 87 patients in the fresh FMT group. In the modified intention-to-treat group, clinical resolution with up to 2 FMT treatments was reported in 81 (75.0%) of 108 patients in the frozen FMT group and 78 (70.3%) of 111 patients in the fresh FMT group. The difference between groups was within the 15% noninferiority margin and thus frozen FMT was considered noninferior to fresh FMT.

A review by Ramai et al (2020) also included a subgroup analysis of donor relation. Results demonstrated that cure rates were not significantly influenced by whether FMT used unrelated or a mix of related and unrelated donors (94.5% and 95.7%, respectively).

Lee et al (2019) performed a prospective study assessing the long-term durability and safety of FMT for patients with recurrent or refractory CDI. Ninety-four patients underwent FMT via retention enema between 2008 to 2012; 32 patients were unreachable and 37 were deceased 4 to 8 years later for a follow-up survey. Twenty-three of the remaining 25 patients completed the questionnaire. No CDI recurrences were reported in patients treated with FMT. Twelve of 23 participants (52.2%) received at

least 1 course of antibiotics for treatment of a condition other than CDI. Nine participants (40.9%) received probiotics. Current health was self-reported as "much better" in 17 patients (73.9%) or "somewhat better" in 3 patients (13.0%). The authors concluded that FMT for recurrent or refractory CDI appears to be durable at 4 to 8 years following treatment, even after receiving non-CDI antibiotic therapy.

UpToDate review, “Treatment of irritable bowel syndrome in adults” (Wald, 2025) states, “(w)e do not recommend FMT in the treatment of IBS, as published trials report inconsistent results and methodologic limitations. In one randomized trial of 90 patients with IBS-D and IBS with mixed bowel habits, fresh or frozen FMT administered via colonoscopy improved IBS symptom severity scores at three months compared with placebo (65 versus 43 percent). However, this difference was not sustained over time, and the study did not include baseline or follow-up evaluation of fecal microbial diversity. Other randomized trials have not shown any benefit of FMT over placebo. Additional studies are needed to determine if there are subgroups of patients who may benefit from FMT and the optimal FMT dose.”

POSITION STATEMENT:

Fecal microbiota transplantation **meets the definition of medical necessity** for treatment of individuals with recurrent Clostridium difficile infection when:

- There have been at least 2 recurrences that are refractory to standard antibiotic treatment

Fecal microbiota transplantation for all other conditions is considered **experimental or investigational.** There is insufficient published clinical evidence to support the safety and effectiveness of FMT in conditions other than recurrent Clostridium difficile infection.

BILLING/CODING INFORMATION:

CPT Coding:

44705	Preparation of fecal microbiota for instillation, including assessment of donor specimen
0780T	Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract

HCPCS Coding:

G0455	Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen

ICD-10 Diagnosis Codes That Support Medical Necessity:

A04.7	Enterocolitis due to Clostridium difficile

REIMBURSEMENT INFORMATION:

Refer to section entitled **POSITION STATEMENT**.

PROGRAM EXCEPTIONS:

Federal Employee Program (FEP): Follow FEP guidelines.

State Account Organization (SAO): Follow SAO guidelines.

Medicare Advantage products: No National Coverage Determination (NCD) and/or Local Coverage Determination (LCD) were found at the time of the last guideline review date.

If this Medical Coverage Guideline contains a step therapy requirement, in compliance with Florida law 627.42393, members or providers may request a step therapy protocol exemption to this requirement if based on medical necessity. The process for requesting a protocol exemption can be found at Coverage Protocol Exemption Request.

DEFINITIONS:

None applicable.

RELATED GUIDELINES:

None applicable.

OTHER:

None applicable.

Florida Statute 765.523 Discrimination in access to anatomical gifts and organ transplants prohibited. (excerpt)

(d) "Organ transplant" means the transplantation or transfusion of a part of a human body into the body of another individual for the purpose of treating or curing a medical condition.

Florida Statute 627.64197 Coverage for organ transplants.—A health insurance policy issued, delivered, or renewed on or after July 1, 2020, in this state by an insurer which provides coverage for organ transplants on an expense-incurred basis may not deny coverage for an organ transplant solely on the basis of an insured's disability. This section may not be construed to require such insurer to provide coverage for an organ transplant that is not medically necessary. For purposes of this section, the term "organ transplant" has the same meaning as in s. 765.523.

Florida Statute 627.65736 Coverage for organ transplants.—A group health insurance policy delivered, issued, or renewed on or after July 1, 2020, in this state by an insurer or nonprofit health care services plan which provides coverage for organ transplants on an expense-incurred basis may not deny coverage for an organ transplant solely on the basis of an insured's disability. This section may not be construed to require such insurer or nonprofit health care service plan to provide coverage for an organ transplant that is not medically necessary. For purposes of this section, the term "organ transplant" has the same meaning as in s. 765.523.

Florida Statute 641.31075 Coverage for organ transplants.—A health maintenance contract issued or renewed on or after July 1, 2020, in this state by a health maintenance organization which provides coverage for organ transplants may not deny coverage for an organ transplant solely on the basis of a subscriber's disability. This section may not be construed to require such health maintenance organization to provide coverage for an organ transplant that is not medically necessary. For purposes of this section, the term "organ transplant" has the same meaning as in s. 765.523.

REFERENCES:

1. Allegretti JR, Feuerstadt P, Knapple WL, et al. Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants with Inflammatory Bowel Disease in PUNCH CD3-OLS. Inflamm Bowel Dis. 2025 Aug 1;31(8):2112-2122.
2. College of Gastroenterology (ACG). Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. February 2013). Accessed at http://gi.org on 07/22/14.
3. Aroniadis OC, Brandt LJ. Intestinal microbiota and the efficacy of fecal microbiota transplantation in gastrointestinal disease. Gastroenterol Hepatol (N Y). 2014 Apr;10(4):230-7.
4. Blue Cross Blue Shield Association. 2.01.92 - Fecal Microbiota Transplantation, 12/25.
5. Bouri S, Hart A. Fecal microbial transplantation: an update. Curr Opin Clin Nutr Metab Care. 2018 Sep;21(5):405-410. doi: 10.1097/MCO.0000000000000488. PMID: 29939968.

6. Cammarota G, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017 Apr;66(4):569-580.
7. Choi HH, Cho YS.Fecal Microbiota Transplantation: Current Applications, Effectiveness, and Future Perspectives. Clin Endosc. 2016 May;49(3):257-65.
8. Chun M, Tun KM, Vongsavath T, et al. Fecal Microbiota Transplantation for Chronic Pouchitis: A Systematic Review and Meta-Analysis. Microorganisms. 2024 Nov 26;12(12):2430.
9. ClinicalTrials.gov. NCT01972334, Stool Transplant in Pediatric Patients With Recurring C Difficile Infection. Last updated March 2014.
10. ClinicalTrials.gov. NCT01226992, Oral Vancomycin Followed by Fecal Transplant Versus Tapering Oral Vancomycin. Last updated January 2013.
11. ClinicalTrials.gov. NCT01545908, Fecal Biotherapy for the Induction of Remission in Active Ulcerative Colitis.Last updated April 2014.
12. ClinicalTrials.gov. NCT01793831, Standardized Fecal Microbiota Transplantation for Crohn Diseases. Last updated December 2013.
13. ClinicalTrials.gov. NCT01398969, Multi-Centre Trial of Fresh vs. Frozen-and-Thawed HB T(Fecal Transplant)for Recurrent CDI. Last updated February 2014.
14. Cohen NA, Maharshak N. Novel Indications for Fecal Microbial Transplantation: Update and Review of the Literature. Dig Dis Sci. 2017 May;62(5):1131-1145. doi: 10.1007/s10620-017-4535-9. Epub 2017 Mar 17. PMID: 28315032.
15. Drekonja DM, Shaukat A, Huang Y, et al. A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection. Clin Infect Dis. 2025 Feb 5;80(1):52-60.
16. Du C, Luo Y, Walsh S, Grinspan A. Oral Fecal Microbiota Transplant Capsules Are Safe and Effective for Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. J Clin Gastroenterol. 2021 Apr 1;55(4):300-308. doi: 10.1097/MCG.0000000000001495. PMID: 33471490.
17. Duo H, Yang Y, Zhang G, et al. Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials. Front Pharmacol. 2024 Oct 17; 15:1430724.
18. ECRI Institute Emerging Technology Report: Fecal Microbiota Transplantation for Treating Recurrent Clostridium difficile Infection (06/20/13).
19. ECRI Institute Health Technology Forecast: Fecal microbiota transplantation concept developed into synthetic stool alternative for C. difficile infection (01/18/13).
20. ECRI Institute Health Technology Forecast: Study suggests fecal transplant is more effective than vancomycin for recurrent Clostridium difficile infection (01/25/13).
21. Fairhurst NG, Travis SPL. Why is it so difficult to evaluate faecal microbiota transplantation as a treatment for ulcerative colitis? Intest Res. 2018 Apr;16(2):209-215.
22. First Coast Service Options, Inc. (FCSO). Florida Medicare Part B Local Coverage Determination L29288, Noncovered Services (02/02/09). Retired 09/30/15.
23. First Coast Service Options, Inc. (FCSO). Florida Medicare Part B Local Coverage Determination L33777, Noncovered Services. (10/01/15) Retired 07/01/20.
24. Florida State Statutes 765.523 – Discrimination in access to anatomical gifts and organ transplants prohibited; Florida Statute 627.64197 – Coverage for organ transplants; 627.65736 – Coverage for organ transplants; and 641.31075 – Coverage for organ transplants. Accessed at http://www.flsenate.gov/.

25. Gallo A, Passaro G, Gasbarrini A, Landolfi R, Montalto M. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol. 2016 Aug 28;22(32):7186-202.

26. Gangwani MK, Aziz M, Aziz A, Priyanka F, Weissman S, Phan K, Dahiya DS, Ahmed Z, Sohail AH, Lee-Smith W, Kamal F, Javaid T, Nawras A, Hart B. Fresh Versus Frozen Versus Lyophilized Fecal Microbiota Transplant for Recurrent Clostridium Difficile Infection: A Systematic Review and Network Meta-analysis. J Clin Gastroenterol. 2023 Mar 1;57(3):239-245. doi: 10.1097/MCG.0000000000001777. PMID: 36656270.

27. Gefen R, Dourado J, Emile SH, et al. Fecal microbiota transplantation for patients with ulcerative colitis: a systematic review and meta-analysis of randomized control trials. Tech Coloproctol. 2025 Apr 17;29(1):103.

28. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis 2011; 53(10):994-1002.

29. Guo B, Harstall C, Louie T et al. Systematic review: faecal transplantation for the treatment of Clostridium difficile-associated disease. Aliment Pharmacol Ther 2012; 35(8):865-75.

30. Heath RD, et al. Fecal microbiota transplantation and its potential therapeutic uses in gastrointestinal disorders. North Clin Istanb. 2018 Feb 12;5(1):79-88.

31. Kao D, et al. Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2017 Nov 28;318(20):1985-1993.

32. Kelly CR, Yen EF, Grinspan AM, et al. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology. 2021 Jan;160(1):183-192.e3. doi: 10.1053/j.gastro.2020.09.038. Epub 2020 Oct 1.

33. Khanna S, Yoho D, Van Handel D, et al. Safety and effectiveness of fecal microbiota, live-jslm (REBYOTA®) administered by colonoscopy for prevention of recurrent *Clostridioides difficile* infection: 8-week results from CDI-SCOPE, a single-arm, phase IIIb trial. Ther Adv Gastroenterol. 2025 Apr 22; 18:17562848251339697.

34. Kousgaard SJ, Cold F, Halkjær SI, et al. The Effect of Non-pooled Multidonor Faecal Microbiota Transplantation for Inducing Clinical Remission in Patients with Chronic Pouchitis: Results from a Multicentre, Randomised, Double-blinded, Placebo-controlled Trial [MicroPouch]. J Crohns Colitis. 2024 Nov 4;18(11):1753-1766.

35. Lee CH, Chai J, Hammond K, Jeon SR, Patel Y, Goldeh C, Kim P. Long-term durability and safety of fecal microbiota transplantation for recurrent or refractory Clostridioides difficile infection with or without antibiotic exposure. Eur J Clin Microbiol Infect Dis. 2019 Sep;38(9):1731-1735. doi: 10.1007/s10096-019-03602-2. Epub 2019 Jun 5. PMID: 31165961.

36. Lee CH, Steiner T, Petrof EO, Smieja M, Roscoe D, Nematallah A, Weese JS, Collins S, Moayyedi P, Crowther M, Ropeleski MJ, Jayaratne P, Higgins D, Li Y, Rau NV, Kim PT. Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial. JAMA. 2016 Jan 12;315(2):142-9. doi: 10.1001/jama.2015.18098.

37. Mamo Y, Woodworth MH, Wang T, Dhere T, Kraft CS. Durability and Long-term Clinical Outcomes of Fecal Microbiota Transplant Treatment in Patients With Recurrent Clostridium difficile Infection. Clin Infect Dis. 2018 May 17;66(11):1705-1711. doi: 10.1093/cid/cix1097.

38. Mattila E, Uusitalo-Seppala R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology 2012;142:490-496.

39. McCarville JL, Caminero A, Verdu EF.Novel perspectives on therapeutic modulation of the gut microbiota. Therap Adv Gastroenterol. 2016 Jul;9(4):580-93.

40. Merrick B, Prossomariti D, Allen E, et al. Faecal microbiota transplant to Eradicate gastrointestinal carriage of Antibiotic-Resistant Organisms (FERARO): A feasibility randomised controlled trial. J Infect. 2025 Jul;91(1):106504.

41. National Institute for Health and Care Excellence. Interventional Procedure Guidance (IPG) 485: Faecal microbiota transplant for recurrent Clostridium difficile infection. March 2014. Accessed at https://www.nice.org.uk/.

42. National Institute for Health and Care Excellence. Research Recommendation IPG485/1. June 2015. Accessed at https://www.nice.org.uk/.

43. Nicholson MR, Mitchell PD, et al. Efficacy of Fecal Microbiota Transplantation for Clostridium difficile Infection in Children. Clin Gastroenterol Hepatol. 2020 Mar;18(3):612-619.e1. doi: 10.1016/j.cgh.2019.04.037. Epub 2019 Apr 19.

44. Petrof EO, Gloor GB, Vanner SJ et al. Stool substitute transplant therapy for the eradication of Clostridium difficile infection: 'RePOOPulating' the gut. Microbiome 2013; 1(1):3.

45. Postigo R, Kim JH. Colonoscopic verus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review of pooled analysis. Infection. 2012;40:643-648.

46. Ramai D, Zakhia K, Fields PJ, Ofosu A, Patel G, Shahnazarian V, Lai JK, Dhaliwal A, Reddy M, Chang S. Fecal Microbiota Transplantation (FMT) with Colonoscopy Is Superior to Enema and Nasogastric Tube While Comparable to Capsule for the Treatment of Recurrent Clostridioides difficile Infection: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 Feb;66(2):369-380. doi: 10.1007/s10620-020-06185-7. Epub 2020 Mar 12. PMID: 32166622.

47. Ray A, Smith R, Breaux J. Fecal Microbiota Transplantation for Clostridium difficile Infection: The Ochsner Experience. Ochsner J. 2014 Winter;14(4):538-44.

48. Rokkas T, Gisbert JP, Gasbarrini A, Hold GL, Tilg H, Malfertheiner P, Megraud F, O'Morain C. A network meta-analysis of randomized controlled trials exploring the role of fecal microbiota transplantation in recurrent Clostridium difficile infection. United European Gastroenterol J. 2019 Oct;7(8):1051-1063. doi: 10.1177/2050640619854587. Epub 2019 May 27.

49. Rossen NG, MacDonald JK, de Vries EM, D'Haens GR, de Vos WM, Zoetendal EG, Ponsioen CY. Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. World J Gastroenterol. 2015 May 7;21(17):5359-71.

50. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. ACG Clinical Guideline Update: Ulcerative Colitis in Adults. Am J Gastroenterol. 2025 Jun 3;120(6):1187-1224.

51. Schenck LP, Beck PL, MacDonald JA. Gastrointestinal dysbiosis and the use of fecal microbial transplantation in Clostridium difficile infection. World J Gastrointest Pathophysiol. 2015 Nov 15;6(4):169-80.

52. Shen ZH, et al. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018 Jan 7;24(1):5-14.

53. Shi Y, Dong Y, Huang W, Zhu D, Mao H, Su P. Fecal Microbiota Transplantation for Ulcerative Colitis: A Systematic Review and Meta-Analysis. PLoS One. 2016 Jun 13;11(6):e0157259.

54. Sung H, Kim SW, Hong M, Suk KT. Microbiota-based treatments in alcoholic liver disease. World J Gastroenterol. 2016 Aug 7;22(29):6673-82.

55. Tariq R, Pardi DS, Bartlett MG, Khanna S. Low Cure Rates in Controlled Trials of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis. Clin Infect Dis. 2019 Apr 8;68(8):1351-1358. doi: 10.1093/cid/ciy721.

56. Tun KM, Hsu M, Batra K, Lo CH, Laeeq T, Vongsavath T, Mohammed S, Hong AS. Efficacy and Safety of Fecal Microbiota Transplantation in Treatment of Clostridioides difficile Infection among Pediatric Patients: A Systematic Review and Meta-Analysis. Microorganisms. 2022 Dec 12;10(12):2450. doi: 10.3390/microorganisms10122450.

57. United States Food and Drug Administration (FDA). Guidance for Industry: Enforcement policy regarding investigational new drug requirements for use of fecal microbiota for transplantation to treat Clostridium difficile infection not responsive to standard therapies. (July 2013). Accessed at http://www.fda.gov on 07/22/14.
58. UpToDate. Fecal microbiota transplantation for treatment of Clostridioides difficile infection. 2025. Accessed at uptodate.com.
59. UpToDate. Treatment of irritable bowel syndrome in adults. 2025. Accessed at uptodate.com.
60. Van Nord E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013;368:407-415.
61. Verbeke F, et al. Faecal microbiota transplantation: a regulatory hurdle? BMC Gastroenterol. 2017 Nov 28;17(1):128.
62. Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012. PMID: 28164849.
63. Wang AY, Popov J, Pai N. Fecal microbial transplant for the treatment of pediatric inflammatory bowel disease. World J Gastroenterol. 2016 Dec 21;22(47):10304-10315.
64. Wang M, Xie X, Zhao S, et al. Fecal microbiota transplantation for irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials. Front Immunol. 2023 May 18; 14:1136343.
65. Wang Y, Zheng F, Liu S, Luo H. Research Progress in Fecal Microbiota Transplantation as Treatment for Irritable Bowel Syndrome. Gastroenterol Res Pract. 2019 Dec 1;2019:9759138. doi: 10.1155/2019/9759138.
66. Wang ZK, Yang YS, Chen Y, Yuan J, Sun G, Peng LH. Intestinal microbiota pathogenesis and fecal microbiota transplantation for inflammatory bowel disease. World J Gastroenterol. 2014 Oct 28;20(40):14805-20.
67. Wei Y, Gong J, Zhu W, Guo D, Gu L, Li N, Li J. Fecal microbiota transplantation restores dysbiosis in patients with methicillin resistant Staphylococcus aureus enterocolitis. BMC Infect Dis. 2015 Jul 11;15:265.
68. Wei Y, Zhu W, Gong J, Guo D, Gu L, Li N, Li J. Fecal Microbiota Transplantation Improves the Quality of Life in Patients with Inflammatory Bowel Disease. Gastroenterol Res Pract. 2015;2015:517597.
69. Zanella Terrier MC, Simonet ML, Bichard P, Frossard JL. Recurrent Clostridium difficile infections: The importance of the intestinal microbiota. World J Gastroenterol. 2014 Jun 21;20(23):7416-7423.

COMMITTEE APPROVAL:

This Medical Coverage Guideline (MCG) was approved by the Florida Blue Medical Policy and Coverage Committee on 08/27/26.

09/15/14	New Medical Coverage Guideline.
09/15/15	Scheduled review. Maintained position statement and updated references.
11/01/15	Revision: ICD-9 Codes deleted.
08/15/16	Scheduled review. Maintained Position Statement section. Updated references.
08/15/17	Scheduled review. Maintained Position Statement section. Updated references. Reformatted guideline.
08/15/18	Scheduled review. Position statement maintained. Updated references.
08/15/19	Scheduled review. Maintained position statement and updated references.
07/01/20	Revision: added Florida statute language regarding discrimination in access to anatomical gifts and coverage of organ transplants. Updated references.

12/15/20	Scheduled review. Revised description, maintained position statement and updated references.
02/15/22	Scheduled review. Revised description and position statement. Updated references.
01/01/23	Annual CPT/HCPCS coding update. Added 0780T.
05/25/23	Update to Program Exceptions section.
01/01/24	Position statements maintained.
10/15/24	Scheduled review. Revised description, maintained position statement and updated references.
09/15/25	Scheduled review. Revised description, maintained position statement and updated references.
09/15/26	Review; no change in position statement. Updated references.